New radioactive drug aims to hit bone tumors while sparing marrow
NCT ID NCT06982222
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 43 times
Summary
This early-phase trial tests a new radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers want to find the safest dose and see if it can slow or shrink the tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tin-117m-DTPA (a radioactive drug that targets bone tumors)
What this could lead to
If it works, this could lead to a new treatment option that slows or shrinks bone metastases with less harm to bone marrow.
What could go wrong
This is a very early Phase 1 trial with only 24 people, so safety and dosing are still being figured out. It may not shrink tumors or may cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.